Last reviewed · How we verify
Ketorolac Tromethamine Injection
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Moderate to severe acute pain (postoperative or perioperative), Short-term pain management in hospitalized patients.
At a glance
| Generic name | Ketorolac Tromethamine Injection |
|---|---|
| Also known as | Ketorolac Tromethamine; NDC 63323-162-02; J Code J1885 |
| Sponsor | UConn Health |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
By blocking COX-1 and COX-2 enzymes, ketorolac reduces the production of prostaglandins, which are mediators of inflammation, pain, and fever. The injectable formulation provides rapid onset of action, making it suitable for acute moderate-to-severe pain management in perioperative and postoperative settings. Its potency as an NSAID makes it effective for short-term use, though prolonged use carries risks of gastrointestinal, renal, and cardiovascular adverse effects typical of the drug class.
Approved indications
- Moderate to severe acute pain (postoperative or perioperative)
- Short-term pain management in hospitalized patients
Common side effects
- Gastrointestinal bleeding or ulceration
- Renal impairment or acute kidney injury
- Dyspepsia or abdominal pain
- Headache
- Dizziness
- Cardiovascular events (myocardial infarction, stroke)
Key clinical trials
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients (PHASE4)
- NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis (PHASE3)
- Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy (PHASE3)
- NSAIDs Stent Study (EARLY_PHASE1)
- Comparing Intramuscular Fentanyl and Ketorolac With Nerve of Arnold (NOA) Block for Bilateral Myringotomy (PHASE4)
- IV Ketorolac on Platelet Function Post-Cesarean Delivery (PHASE4)
- Intramuscular Ketorolac at Two Single-Dose Regimens (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketorolac Tromethamine Injection CI brief — competitive landscape report
- Ketorolac Tromethamine Injection updates RSS · CI watch RSS
- UConn Health portfolio CI